Research paperDesign, synthesis and biological activities of novel oxazolo[4,5-g]quinazolin-2(1H)-one derivatives as EGFR inhibitors

Add time:09/06/2019    Source:sciencedirect.com

A series of oxazolo[4,5-g]quinazolin-2(1H)-one derivatives employing Erlotinib as lead compound were synthesized and evaluated for their EGFR inhibition activity. These compounds having variation at the 1 and 8-position, included ether and esters hydrophilic side-chain and aromatic head fragment, respectively. All these compounds were evaluated by EGFR inhibition and two anti-proliferation assays in vitro. Four compounds were found more potent than Erlotinib in EGFR-TK assay. Furthermore, compounds 18, 42 and 50 also had good to excellent anti-proliferation activity against human epidermoid cancer cell line (KB) and renal cell carcinoma cell line (A498). Finally, compound 50 presented remarkably higher inhibition efficacy towards tumor growth than Erlotinib in a mouse lewis lung cancer (LLC) xenograft model. Furthermore, compound 50 displayed the most distinguished effect on extending the survival period of the tumor-bearing mice.

We also recommend Trading Suppliers and Manufacturers of 2-[(4-ETHOXY-PHENYLAMINO)-METHYL]-PHENOL (cas 104768-31-2). Pls Click Website Link as below: cas 104768-31-2 suppliers

Prev:A new synthetic approach to polysubstituted-2-pyridones from enamino esters and diethyl ethoxymethylenemalonate under catalyst- and solvent-free conditions
Next:Uncatalyzed solventless Diels–Alder reaction of 2-amino-3-nitroacrylate: synthesis of new epimeric 2-amino-3-nitro-norbornene- and norbornane-2-carboxylic acids)